Vapotherm High Flow Therapy Device

Vapotherm High Flow Oxygen Therapy Device

Vapotherm High Flow System

Effective & Precise Ventilation Support for patients with respiratory distress

• Area of ​​use from newborn to geriatric patients
• Allows patients to eat, talk and sleep comfortably
• It reduces the respiratory rate, allows the secretion to be removed easily and reduces the respiratory load.
• Helps avoid intubation and reduce hospital stay
• Fully integrated system is easy to install and operate
• Security alarms are available to warn of interruptions in therapy.

Water Jacket Air Supply Tube

Vapotherm air supply tube uses the safe, insulating property of warm water to maintain gas temperature and humidity until it reaches the patient.

Medical Grade Steam™

The Vapotherm vapor transfer cartridge injects molecular water vapor into the breathing gas. This unique method of gas humidification helps to retain water in the form of water vapor to better protect respiratory tissues and improve patient comfort.

High Flow Cannula

Slim narrow prong feature Vapotherm nasal cannula design maximizes expiratory gas evacuation and provides an open system. The Vapotherm high flow system offers different sizes of cannulas that can fit each patient effectively.

Disposable High Flow Patient Circuit

Single use The patient circuit, which can be used for up to 30 days, consists of a disposable water path, steam transfer cartridge, and air supply tube. The completely disposable patient circuit is available in High Flow or Low Flow versions.

High Flow (5-40 L/DK)

Low Flow (1-8    L/DK)

• Forget the hassle and cost of changing circuits every 7-14 days.

Applied Areas

• Newborn intensive care unit

Newborn intensive care unit In cases where a newborn is unable to breathe on his own, a mechanical ventilator will be used to help the newborn breathe. Continuous positive airway pressure (CPAP) may be administered where a newborn is able to breathe on their own but is showing symptoms of respiratory distress. Continuous positive airway pressure is a pressure-based therapy applied with a mask or tightly fitting nasal prongs. It facilitates breathing by applying pressure to help open the lungs and help the baby breathe in.

High-flow therapy is an alternative method of respiratory support for newborn infants and can help avoid such more invasive treatments..

High-flow therapy reduces the work of breathing – the effort required to breathe – by delivering exhaled gas at rates that exceed an infant’s breathing demand. Supplied with a simple, loose-fitting nasal cannula suitable for the infant. The breathing gas is heated and humidified to make it easier to tolerate high flow rates.

As the inhalation gas moves from the Vapotherm Precision Flow unit towards the patient, maintaining the temperature and humidity of the gas is crucial for effective therapy. If the temperature is not maintained, the moisture in the gas may turn into liquid inside the air tube. This situation is known as “rain-out” by respiratory therapists and should be avoided especially in newborn patients, which can have important clinical consequences if even a very small amount of water enters the trachea.

Vapotherm eliminates the rain-out situation by using medical humidification vapor and fully heating the humidified gas to the patient. The delivery tube, insulated with a water jacket that transports the gas, is never too hot to put near baby’s skin, but feels warm to the touch.

Water jacket insulation also allows the Vapotherm delivery hose to be placed inside the radiant heater. The size of the delivery tube and loose fitting nose prongs allow the parent to hold the infant while in treatment.

While clinical studies in recent years have shown improved results regarding nasal trauma, High Flow Therapy therapy has shown that continuous positive airway pressure (CPAP) application is equivalent to providing respiratory support to newborns. There is a substantial amount of resources available on supporting newborn infants with high-flow therapy.

• The Pediatric Intensive Care Unit (PICU)

The Pediatric Intensive Care Unit (PICU) provides the highest level of medical care to sick children. Children whose medical needs cannot be met in the general care floor or who have just come out of surgery are usually referred to the Pediatric Intensive Care Unit. The Pediatric Intensive Care Unit delivers treatments and uses medical equipment that may not be available in other care areas, as well as intensive nurse care.

The length of stay depends on the severity of the child’s condition and the health care team will decide when the child can be released.

Serious breathing problems such as bronchitis and asthma are common reasons for admission to the Pediatric Intensive Care Unit. Respiratory support may also be necessary for patients recovering from surgery. In cases where a child cannot breathe on their own, a mechanical ventilator will be used to help the newborn breathe. non-invasive positive pressure system such as CPAP and BiPAP or an oxygen mask only can be used when symptoms of respiratory distress are present. It facilitates breathing by applying pressure to help open the lungs and help the child breathe in.

High Flow Therapy therapy is an alternative method of respiratory support for children that can help avoid such more invasive treatments with a simple nasal cannula interface.

• Emergency

Patients of all ages, whatever their health condition, seek emergency care from doctors, nurses, respiratory therapists and other clinicians. Staff treat and stabilize patients according to the severity of illness or injury. Depending on their health status, patients are discharged or transferred to the general care floor or intensive care unit.

Some people entering the Emergency Room experience breathing difficulties.

The integrated Precision Flow system is easy to set up and operate in an Emergency Room environment, providing rapid treatment of hypoxia and hypercapnia to stabilize patients experiencing acute distress. Rapid stabilization can reduce ICU admissions compared to non-invasive positive pressure ventilation. The system delivers precisely heated and humidified air that can increase FiO2 levels (21%) from room air to 100% and increase flow rates to 40 LPM to maximize support for the individual patient. CO2 is expelled from the nasopharyngeal space at the end of each breath and is replaced by clean gas infused with medical steam. The patient breathes through the upper airway to reduce the total work of breathing

• Post-Acute Care

Post-Acute Care facilities offer patients who need significant medical support a transition between an acute care hospital   and home care or chronic care. Patients are transferred from acute care hospitals to post-acute care facilities when they need more complex care at home than they can receive from their families, but less complex and less expensive than care provided in an acute care hospital. Post-acute care facilities provide ongoing care to patients recovering from an acute illness, injury, or exacerbation of a chronic illness. The most common types of post-acute care facilities are Long Term Acute Care Hospitals (LTACH), Skilled Patient Care Facilities (SNF) and Inpatient Rehabilitation Facilities (IRF).

Patients in post-acute care facilities require significant respiratory support as part of their care, including:

• Withdrawal from respiratory support (mechanical ventilation, non-invasive ventilation),
• Removal or decannulation of tracheostomy tubes,
• Physical or pulmonary rehabilitation to provide strength for daily life at home and to achieve an appropriate level of self-care,
• Relief from acute respiratory distress,
• Treating shortness of breath.

Discontinuation of Ventilator and Tracheostomy

Vapotherm heated and humidified high-flow therapy can be an effective tool throughout the ventilator and tacheostomy cutting process by delivering humidified oxygen with a track ring or mask to mobilize secretions, but can also be used as light respiratory support during closure attempts.

Humidification of the Tracheostomy

During spontaneous breathing trials, Vapotherm delivers sensitive FiO2 gas to the track ring or mask at body temperature and humidity, helping to mobilize secretions and clear the airway.

 Respiratory Support – During shutdown attempts, only the Vapotherm patient interface needs to be converted from a track adapter to a nasal cannula to continue to support the patient’s need for supplemental oxygen with optimally heated and humidified gas.

Respiratory Support for Acute Respiratory Difficulties

Vapotherm can be used as a lifesaving and interruption therapy for non-tracheostomy patients experiencing acute respiratory distress to avoid more invasive interactions such as non-invasive positive pressure ventilation and mechanical ventilation. Vapotherm effectively disperses oxygen levels between 21-100% while removing carbon dioxide from the upper respiratory tract, reducing the patient’s breathing work of 11-13%. It does this with a nasal cannula and allows the patient to eat, talk and sleep comfortably while receiving a high level of respiratory support.

Treating Shortness of Breath (Dyspnea)

Vapotherm High Flow Therapy (HFT) therapy helps reduce symptoms by identifying the underlying causes of shortness of breath symptoms:

Hypoxia: Insufficient amount of oxygen reaching the tissues

-Vapotherm can deliver oxygen at gradual levels between 21-100%.

Hypercapnia: Excess carbon dioxide in the bloodstream

–Vapotherm continuously delivers fresh gas to the upper respiratory tract to reduce or eliminate the amount of inhaled carbon dioxide with each breath.

• Palliative Care

Palliative care is generally responsible for the physical, emotional and spiritual care of the patient and family.

It is coordinated by a group of health professionals, including doctors, nurses, social workers and others.

Dyspnea (shortness of breath) is most common among palliative care and hospice care patients.

one of the complaints. Dyspnea can be so painful for patients that it is one of the most common reasons palliative care patients visit emergency rooms. Although the most common causes of dyspnea are problems in the lungs such as pneumonia, bronchitis and emphysema, problems in other organs such as the heart, liver and kidneys can also cause this perception.

Palliative Care

The Vapotherm high flow system treats the underlying causes of shortness of breath (dyspnea) by delivering ideally tailored, high flow gas through a nasal cannula. Vapotherm High Flow Therapy (HFT) therapy helps reduce symptoms by identifying the underlying causes of shortness of breath symptoms.

The most commonly used treatment for dyspnea in palliative care patients today is the administration of opioid drugs such as morphine. This reduces the pain and anxiety associated with shortness of breath, but can reduce a patient’s consciousness and ability to relate to family and caregivers. The second most common treatment is oxygen delivery with a low flow rate with a nasal cannula. Oxygen with a low flow rate can reduce hypoxia due to dyspnea, but has not been shown to be very effective in reducing the work of breathing, especially for which some patients suffer so much.

Respiratory Disorders

• General Respiratory Failure (Key treatment option in respiratory failure caused by Covid-19)
• bronchitis (RSV)

Bronchitis is an infection of the bronchial passages of your lungs. In response to this infection, the passages of the lung are filled with phlegm, the air passage is blocked, and breathing becomes difficult. In children, the most common cause of this infection is Respiratory Syncytial Virus (RSV). Respiratory Syncytial Virus is very contagious and is very common from autumn to spring. Many children get Respiratory Syncytial Virus at some point in their childhood. In many cases, it presents as a cold and does not require medical attention. However, children exposed to Respiratory Syncytial Virus face a much more serious reaction that leads to bronchitis and hospitalization.

Children treated in hospital for Respiratory Syncytial Virus may need respiratory support while the infection is being treated.

Vapotherm HFT therapy provides a high level of respiratory support with a nasal cannula. Inhalation gas is delivered at high flow rates that force exhaled air out of the nasopharyngeal space. This removes exhaled carbon dioxide and ensures that every breath that reaches the lungs is mostly clean, high-oxygen breathing gas. To provide these high flow rates, the gas is heated and humidified. High humidity means that patients can take high flows comfortably and it also has the effect of removing phlegm in the respiratory tract. Since it is given with a simple open system nasal cannula, it is easy for the patient to open the airway by coughing. This increases airway permeability, which causes more inhaled gas reaching the alveoli to increase ventilation and oxygenation.

Clinical Use and Adjustment of Flow Rates

The level of the flow rate should be adjusted to be sufficient to clear the dead volume of the airway and reduce the work of breathing. The size of the dead volume of the respiratory tract in children varies according to the child’s height and age. The primary indicator of an appropriate flow rate is the clinical observation of a reduction in breathing work and breathing rate. Oxygenation is managed by adjusting the FiO2 gas. When symptoms subside, the patient can be weaned off treatment by reducing flow rates and FiO2 gas, respectively.

• Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD) is the general name for a class of progressive lung conditions consisting of chronic bronchitis, emphysema, refractory asthma, and some forms of bronchiectasis. Because of the increased resistance to airflow in the lungs, it is difficult for patients with chronic obstructive pulmonary disease to breathe. The two most common forms of chronic obstructive pulmonary disease are chronic bronchitis, which causes prolonged coughing with sputum, and emphysema, which causes deterioration of lung tissue. Chronic obstructive pulmonary disease is characterized by increasing difficulty breathing and may develop gradually over the years without noticeable breathing difficulties until later stages of the disease. Initial symptoms are usually difficulty breathing, coughing frequently (with or without phlegm), wheezing, and chest tightness. Patients with chronic obstructive pulmonary disease have some complications, most likely due to infection or irritation of the respiratory system. Treatments for chronic obstructive pulmonary disease include bronchodilator and anti-inflammatory drug treatments to reduce resistance to airflow, as well as oxygen therapy to increase oxygenation to compensate for decreased breathing efficiency. Baseline symptoms may be hampered by the drying effect of long-term treatments, such as oxygen supplementation, which reduces mucociliary condition leading to more frequent xacerbations and secondary complications such as pneumonia.

Vapotherm High Flow Therapy treatment is usually in the acute flow environment while in exacerbation.

It is used to help patients. High Flow Therapy Therapy is a suitable method to reduce the work of breathing and to treat breathing difficulties. There is a movement mechanism that uses the upper pharynx as a fresh gas reservoir. High Flow Therapy therapy delivers fresh gas with each breath and provides additional support to remove exhaled CO2 gas from the nsopharyngeal space. High Flow Therapy therapy increases the rate of fresh gas in each breath, as fresh gas is discharged into the anatomical dead volume. It also removes CO2 gas from the patient’s respiratory tract. This combination of oxygenation and evacuation of exhaled CO2 affects both hypoxia and hypercapnia. High Flow Therapy supplementation may be sufficient to prevent non-invasive positive pressure ventilation in exacerbated patients. Vapotherm High Flow therapy (HFT) delivers accurately mixed oxygen mixtures that are tailored to the ideal temperature and humidity with a nasal cannula at flow rates that clear dead volume. High Flow therapy provides precise control of oxygen delivery. This precise control is especially important in end-stage chronic obstructive pulmonary patients who depend on blood oxygen levels to stimulate respiratory effort.

• Pneumonia

Pneumonia is inflammation of the alveoli, the air sacs of the lung, where oxygen and CO2 exchange occur. Inflammation can be caused by bacteria, viruses, or fungi that cause the air sacs to fill with fluid or inflammation. This creates symptoms of chest tightness, sputum or inflammatory cough, fever, chills and difficulty breathing in the patient. Other symptoms that may occur are chest pain, feeling tired and exhausted, nausea and vomiting. Typically, pneumonia occurs when the immune system is compromised due to illness or when newborn babies are not fully developed.

Pneumonia can be acquired in the hospital or in the community outside the hospital and other healthcare facilities. Hospital-acquired pneumonia may be more difficult to spot as bacteria that may be more resistant to antibiotics. A subtype of hospital-acquired prophylaxis is ventilator-associated pneumonia (VAP), which develops in patients 48 hours or more after mechanical ventilation is given via an endotracheal tube or tracheostomy. There is also aspiration pneumonia caused by food, saliva, liquids, or vomit re-entering the lungs.

Vapotherm high flow therapy may be an effective tool in the treatment of pneumonia. Vapotherm provides removal of carbon dioxide from the upper airway and effective oxygen delivery (up to 100%) to help reduce the work of breathing for the person experiencing shortness of breath and/or breathing difficulties. This relieves respiratory distress, while antibiotics or other treatments resolve the infection.

Successful implementation of HFT can also avoid the need for more invasive treatments such as two-stage ventilation and mechanical ventilation. Two-stage ventilation is contraindicated for patients with pneumonia and mechanical ventilation is a known cause of pneumonia.

Vapotherm, which provides air and oxygen at body temperature with humidification,

Not only does it help prevent drying and damage, it also helps moisturize the upper respiratory tract and improve the mobilization of their secretions and airway clearance.

• Congestive Heart Failure

Heart failure occurs when the contraction of the heart muscle is not strong enough to maintain the blood flow that meets the body’s demand. This does not mean that the heart has stopped pumping blood, rather it means that the heart is not working effectively at circulating blood throughout the body. With this reduced blood flow rate, the kidneys are triggered to retain fluid in an effort to restore the apparently low circulating blood volume. This increased water retention leads to congestion in various parts of the body, including the lungs. And thus, Congestive Heart Failure (CHF) disease occurs.

CHF patients experiencing a crisis may need respiratory support as medications work to reduce fluid retention and pulmonary edema.

Congestive Heart Failure and Pulmonary Edema

HF can cause some pulmonary symptoms such as shortness of breath and exercise intolerance.

Fluid retention in the lungs may be exacerbated because HF is associated with normal right heart function, which normally pumps blood to the lungs, and decreased performance of the left part of the heart, which pumps blood from the lungs to the rest of the body. As a result, the congestion in the lungs may cause the fluid to go beyond the alveolar walls and accumulate in the areas normally reserved for air in the lungs. This results in reduced oxygen uptake and therefore reduced oxygen delivery to the remaining parts of the body. Vapotherm High Flow therapy (HFT) is used extensively to support patients with respiratory failure secondary to CHF. HFT delivers conditioned oxygen-rich gas at high flow rates and clears nasopharyngeal dead space between breathing. With each breath, the patient inhales only freshly oxygenated gas. By creating an oxygen tank, the patient’s breathing work is alleviated. This improved breathing efficiency is important with CHF because the increased respiratory effort (respiratory muscle work) secondary to heart-related lung congestion corresponds to greater demand on the deteriorated heart. HFT may further help relieve symptoms of worsening CHF by reducing the workload of breathing.

The flow rate should be adjusted to adequately clear respiratory dead spaces between breaths. In adults, this is usually 25 liters per minute or more, depending on the size of the patient and the severity of respiratory failure. Oxygenation is managed by adjusting FiO2. As symptoms subside, the patient can be withdrawn from therapy by gradually reducing flow rates and FiO2.

• Astım

Asthma is a lifelong disease and inflammatory condition of the small airways or bronchioles that causes narrowing of the airways and increased secretion production. The narrowing diameters of the bronchioles cause patients to be able to breathe, but have difficulty in exhaling while exhaling. Symptoms include wheezing, breathlessness, chest tightness, and a persistent cough. Incomplete exhalation of a full breath causes dynamic hyperinflation and increased effort to breathe. Difficulty breathing makes it difficult to clear excess secretions produced in response to inflammation. The disease is of external origin; that is, the powder is clearly associated with specific antigenic agents such as herbs, animal bran, or food preservatives or the like. This is also known as allergic or atopic asthma. Bronchoconstriction is activated by hypersensitivity to the antigen to which the person is exposed. Non-allergic (intrinsic) asthma is asthma that cannot be directly linked to an antigen to which the person is hypersensitive. Supportive treatment for both types of asthma during an acute attack/crisis is basically the same.

Bronchodilators such as albuterol are widely used to treat restrictive airways associated with asthma by reversing bronchoconstriction through stimulation of the sympathetic nervous system. Sometimes parasympathomimetic drugs such as ipratropium bromide are used to prevent the stimulation of the parasympathetic nervous system, which has a symbiotic effect with the sympathetic agonist. Steroids are often given in severe attacks to help reduce the inflammatory response produced by the disease process. This reduction also helps to reduce excessive secretion production. In general, oxygen therapy is urgently needed in severe attacks or low oxygen levels in the bloodstream to combat hypoxemia. Patients with respiratory failure will be connected to a ventilator and taken to the intensive care unit.

Vapotherm high flow therapy can reduce the work of breathing during an asthma attack/crisis. Vapotherm provides the removal of carbon dioxide and effective oxygen delivery (up to 100%) in the upper respiratory tract to help reduce the work of breathing for the person experiencing shortness of breath and/or respiratory distress. While this relieves respiratory distress, bronchodilators, steroids, or other treatments resolve the infection and narrowing of the airway.

Successful implementation of HFT can also help avoid the need for more invasive treatments such as non-invasive positive pressure ventilation and mechanical ventilation via an endotracheal tube. Giving air and oxygen at body temperature along with humidification, Vapotherm not only helps to prevent the drying and damage of nasal tissues, but also helps to moisturize the upper respiratory tracts and improve the mobilization of their secretions and airway clearance. An additional benefit of this conditioned gas for the asthmatic patient is that this heated gas promotes bronchodilation and relaxation of smooth muscle tissues.

• Turkish Brochure

• English Brochure

Vapotherm High Flow Animation Video

Vapotherm Technology High Flow Therapy Trailer

Water Jacket Air Supply Tube Animation Video

Vapor Animation Video for Medical Use